Minu K. Srivastava
0009-0000-3827-9180
Publication & Citation Trends
Publications
0 total
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial.
Cited by 21
Semantic Scholar
Development and validation of a serum proteomic test for predicting patient outcomes in advanced non-small cell lung cancer treated with atezolizumab or docetaxel
Cited by 1
Semantic Scholar
IMpower010: Genomic profiling and clinical outcomes with adjuvant atezolizumab in early-stage non-small cell lung cancer (eNSCLC).
Cited by 1
Semantic Scholar
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations
Cited by 3
Semantic Scholar
Concordance of response-based clinical trial and machine learning–generated real-world end points.
Cited by 1
Semantic Scholar
Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial
Cited by 23
Semantic Scholar
Clonal hematopoiesis is associated with reduced response to atezolizumab in non-small cell lung cancer
Cited by 1
Semantic Scholar
Digital Versus Manual PD-L1 Scoring in Advanced Non-Small Cell Lung Cancer From the IMpower110 and IMpower150 Trials.
Cited by 3
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(41)
Immunotherapy and Immune Responses
(29)
Immune cells in cancer
(26)
Cancer Genomics and Diagnostics
(25)
Lung Cancer Treatments and Mutations
(18)
Affiliations
University of Maryland, Baltimore
West Los Angeles College
OncoMed (United States)
University of California, Los Angeles
Pfizer (United States)